Shares of Replimune Group, Inc. (REPL) have gained 2.7% over the past four weeks to close the last trading session at $7.16, but there could still be a solid upside left in the stock if short-term ...

Live webcasts of the fireside chat will be available in the Investors section of Replimune’s website at www.replimune.com. A replay will be available for 30 days following the conference. Replimune ...

What if every person you meet, including those you’ve yet to cross paths with, is quietly tethered to you by a single thread you can't even see? That's the premise of the invisible string theory. The ...

Shares of Replimune Group, Inc. (REPL) have gained 0.7% over the past four weeks to close the last trading session at $7.76, but there could still be a solid upside left in the stock if short-term ...

For more than a century, scientists have wondered why physical structures like blood vessels, neurons, tree branches, and other biological networks look the way they do. The prevailing theory held ...

Array Technologies is upgraded to a 'Buy' as regulatory uncertainty eases, demand rebounds, and pricing stabilizes. Q3 bookings surged, driving the order book to $1.9B and signaling robust recovery in ...

The average one-year price target for Replimune Group (NasdaqGS:REPL) has been revised to $10.84 / share. This is an increase of 48.75% from the prior estimate of $7.29 dated September 27, 2025. The ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Replimune misled investors about the prospects of its IGNYTE trial for RP1 (vusolimogene ...

NEW YORK, NY / ACCESS Newswire / September 17, 2025 / Levi & Korsinsky, LLP releases a Podcast regarding Replimune Group, Inc. (REPL) class action securities lawsuit A Class Action lawsuit was filed ...